Make HER first-line count in the maintenance setting in newly diagnosed aOC

Embrace precision medicine for HRD+ aOC, think Lynparza + bevacizumab²

Why is HRD testing important in advanced ovarian cancer?

Homologous recombination deficiency is common in ovarian cancer. Approximately 1-in-2 women with advanced ovarian cancer have HRD-positive tumours (including those with a tBRCAm).^3-5
HRD testing can provide crucial diagnostic information to guide personalised treatment options for patients with newly diagnosed aOC:^1,6

Infographic showing nearly half of aOC patients are HRD+ (incl. BRCAm) and may be eligible for Lynparza in 1L maintenance

VIEW SOLO-1 STUDY

VIEW PAOLA-1 STUDY

How do PARP inhibitors target HRD tumours?

Homologous recombination deficiency (HRD) is the impaired ability of a cell to accurately repair DNA, and is a hallmark of cancer. Lynparza induces cancer cell death by inhibiting PARP, a DNA repair enzyme utilised by HRD tumour cells.⁷

Infographic showing the MOA for Lynparza, a PARP inhibitor

Note: This data is pre-clinical data and should not be extended to the clinical setting. Pre-clinical data suggests a co-targeting mechanism of PARP inhibitors plus anti-angiogenic agents.^8,9

How does HRD testing fit into the patient pathway?

Biomarker testing should be integrated early in the diagnostic pathway, alongside biopsy and histology, to identify BRCA mutations and HRD status. The molecular characteristics of aOC should then be used to direct treatment choices, as recommended by the latest ESMO guidelines.¹⁰
All patients with newly diagnosed, advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer are eligible to be tested for HRD.¹

Infographic showing how HRD testing fits into the ovarian cancer patient pathway

How to request HRD testing

HRD testing is now available through the NHS Genomic Laboratory Hubs (GLH). Please contact your local GLH for more information.

Access materials to help your patients understand genetic testing in aOC

Lynparza tablets therapeutic indications¹

Lynparza tablets are indicated as monotherapy for:

The maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
The maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Lynparza in combination with bevacizumab is indicated for:

The maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

Please consult the SmPC for further information before making any prescribing decisions.

aOC, advanced Ovarian Cancer; BRCAm, BRCA1 or BRCA2 mutation; FIGO, Fédération Internationale de Gynécologie et d’Obstétrique; HR, homologous recombination; HRD, homologous recombination deficiency; NHS GLH, NHS Genomic Laboratory Hub; PARP, poly(ADP-ribose) polymerase; SSB, single strand break; DSB, double strand break; DNA, deoxyribose nucleic acid.

Ray-Coquard I, et al. Ann Oncol. 2023;34:681–692.
Konstantinopoulos PA, et al. Cancer Discov. 2015;5(11):1137-54.
Moschetta M, et al. Ann. Oncol. 2016;27:1449-1455.
Ray Coquard I, et al. N Engl J Med. 2019;381:2416-2428.
Lynparza (olaparib) Summary of Product Characteristics.
Myriad. Myriad myChoice® HRD Technical Specifications. (2017).
O’Connor MJ. Mol Cell. 2015;60:547–560.
Liu JF, et al. Lancet. 2014;15:1207–1214.
Boussios S, et al. Diagnostics (Basel). 2019;9:87.
Ledermann J, et al. Ann Oncol. 2024;35:248–266.

GB-73569 | Date of Preparation: July 2026

Privacy Policy Terms of Use Contact Us Information for General Public Accessibility
Cookie Preferences

GB-73578 | Date of Preparation: July 2026

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).